- Trials with a EudraCT protocol (155)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (2)
155 result(s) found for: Replication.
Displaying page 1 of 8.
EudraCT Number: 2004-004802-26 | Sponsor Protocol Number: SIM-ATOR | Start Date*: 2005-03-23 |
Sponsor Name:Fundació Lluita contra la SIDA | ||
Full Title: ESTUDIO DE LA INFLUENCIA DE LAS ESTATINAS EN LA REPLICACIÓN PLASMÁTICA DEL VIH EN PACIENTES CON INFECCION POR EL VIH-1 QUE INTERRUMPEN EL TRATAMIENTO ANTIRRETROVIRAL | ||
Medical condition: Patients HIV infected | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2012-003312-30 | Sponsor Protocol Number: 2012-24 | Start Date*: 2012-12-12 |
Sponsor Name:ASSISTANCE PUBLIQUE HOPITAUX DE MARSEILLE | ||
Full Title: Interest of preemptive treatment with ganciclovir or acyclovir in patients requiring prolonged mechanical ventilation and have either a cytomegalovirus replication in blood or an herpes simplex vir... | ||
Medical condition: mechanically ventilated patients | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2011-002267-26 | Sponsor Protocol Number: 13071981 | Start Date*: 2012-04-12 | |||||||||||
Sponsor Name:Medizinische Universität Wien | |||||||||||||
Full Title: Hepatitis C in renal transplant recipients – Safety and efficacy of a conversion of immunosuppression to high-dose cyclosporine A and its impact on HCV-replication, parameters of liver function and... | |||||||||||||
Medical condition: renal transplant recipients with hepatitis C | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-000849-50 | Sponsor Protocol Number: MI-CP114 | Start Date*: 2017-12-12 |
Sponsor Name:MedImmune | ||
Full Title: A Phase I Randomized, Double-Blind Trial of the Safety and Immunogenicity of FluMist® A Live, Intranasal Influenza Virus Vaccine vs. Placebo in Immunocompromised Children Ages 5 Through 17 Years of... | ||
Medical condition: The prevention of Influenza Virus in Immunocompromised children ages 5 through 17 years of age. | ||
Disease: | ||
Population Age: Children, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2019-001461-32 | Sponsor Protocol Number: ITATI | Start Date*: 2019-10-25 | |||||||||||
Sponsor Name:IrsiCaixa AIDS Research Institute | |||||||||||||
Full Title: Immune Therapy and Analytical Treatment Interruption in HIV+ participants who received an allogeneic stem cell transplantation (ITATI) | |||||||||||||
Medical condition: HIV+ infected subjects with undetectable replication competent HIV reservoir after allogeneic stem cell transplantation in presence of cART. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-000685-42 | Sponsor Protocol Number: 2DR-study | Start Date*: 2020-04-30 |
Sponsor Name:Ghent University Hospital | ||
Full Title: Virological and immunological assessment in HIV positive participants on 2DR versus 3DR in a prospective randomized controlled switch trial. | ||
Medical condition: human immunodeficiency viruses (HIV) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Trial now transitioned) | ||
Trial results: View results |
EudraCT Number: 2005-003136-22 | Sponsor Protocol Number: GS-US-174-0106 | Start Date*: 2006-05-05 | |||||||||||
Sponsor Name:Gilead Sciences Incorporated | |||||||||||||
Full Title: A Phase 2, Randomized, Double-Blind Study Exploring the Efficacy, Safety and Tolerability of Tenofovir Disoproxil Fumarate (DF) Monotherapy Versus Emtricitabine plus Tenofovir DF Fixed-Dose Combina... | |||||||||||||
Medical condition: Chronic Hepatitis B | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-013917-91 | Sponsor Protocol Number: AIC246-01-II-02 | Start Date*: 2010-02-09 |
Sponsor Name:AiCuris GmbH & Co. KG | ||
Full Title: A randomized, double-blind, placebo controlled trial to evaluate the safety, tolerability and antiviral activity of 12 weeks’ treatment with a new antiviral HCMV drug | ||
Medical condition: Prevention of active human cytomegalovirus (HCMV) replication by re-infection or re-activation in HCMV seropositive patients after human blood precursor cell (HBPC) transplantation | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2011-003067-30 | Sponsor Protocol Number: AI444-043 | Start Date*: 2012-01-11 | |||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||
Full Title: A Phase 3, Open Label Study of Safety and Efficacy with BMS-790052 plus Peg-Interferon Alfa 2a and Ribavirin in Previously Untreated HCV Patients Coinfected with Human Immunodeficiency Virus (HIV) ... | |||||||||||||
Medical condition: Chronic Hepatitis C / HIV-1 co-infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) ES (Completed) GB (Completed) BE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-004825-17 | Sponsor Protocol Number: preTopic17 | Start Date*: 2017-12-06 |
Sponsor Name:Charité Universitätsmedizin Berlin | ||
Full Title: A Proof-of-concept study to investigate the Efficacy of Telbivudine Over Placebo in patients with Parvovirus-associated Inflammatory Cardiomyopathy | ||
Medical condition: Parvovirus B19-induced inflammatory cardiomyopathy | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2011-004464-30 | Sponsor Protocol Number: RIPIM | Start Date*: 2011-11-22 | |||||||||||
Sponsor Name:Institut de Recerca e la SIDA - IrsiCaixa- | |||||||||||||
Full Title: Impact of Raltegravir Intensification on HIV-1-infected Subjects with Complete Viral Suppression under Monotherapy with Protease Inhibitors. A 24-week controlled, open-label, proof-of-concept pilot... | |||||||||||||
Medical condition: HIV-1 infection | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-001288-26 | Sponsor Protocol Number: DASAHIVCURE | Start Date*: 2022-08-18 | |||||||||||
Sponsor Name:IDIBAPS | |||||||||||||
Full Title: Safety, tolerance and antiretroviral activity of dasatinib: a pilot clinical trial in patients with recent HIV-1 infection | |||||||||||||
Medical condition: Recent HIV-1 infection | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-001465-24 | Sponsor Protocol Number: GC-LTFU-001 | Start Date*: 2018-02-26 | |||||||||||
Sponsor Name:Celgene Corporation | |||||||||||||
Full Title: Long-Term Follow-up Protocol for Subjects Treated with Gene-Modified T cells. | |||||||||||||
Medical condition: Defined by parent protocol. The study will enroll all adult and paediatric subjects who received at least one genetically modified T cells infusion in a previous Celgene sponsored study. | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Trial now transitioned) DE (Trial now transitioned) ES (Ongoing) NL (Trial now transitioned) AT (Trial now transitioned) FR (Trial now transitioned) FI (Trial now transitioned) SE (Trial now transitioned) GB (GB - no longer in EU/EEA) NO (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-024496-37 | Sponsor Protocol Number: 1716-12 | Start Date*: 2012-05-04 | |||||||||||
Sponsor Name:Virttu Biologics Limited | |||||||||||||
Full Title: A PHASE I/IIa STUDY OF THE SAFETY, TOLERABILITY AND BIOLOGICAL EFFECT OF SINGLE AND REPEAT ADMINISTRATION OF THE SELECTIVELY REPLICATION-COMPETENT HERPES SIMPLEX VIRUS HSV1716 INTO THE TUMOUR-BEAR... | |||||||||||||
Medical condition: Malignant Pleural Mesothelioma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-002820-33 | Sponsor Protocol Number: 182 | Start Date*: 2013-06-26 | ||||||||||||||||
Sponsor Name:CENTRO DI RIFERIMENTO ONCOLOGICO DI BASILICATA | ||||||||||||||||||
Full Title: FLT F-18 PET/CT in diagnosis, staging and terapy assessmentin tumours with accelereted replication | ||||||||||||||||||
Medical condition: patients complying with cancer for whom is mandatory to know the replicative cellular activty | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-001010-38 | Sponsor Protocol Number: Ahus-NO-COVID-19 | Start Date*: 2020-03-23 | |||||||||||
Sponsor Name:Akershus University Hospital | |||||||||||||
Full Title: NORWEGIAN CORONAVIRUS DISEASE 2019 (NO COVID-19) STUDY: AN OPEN LABELED RANDOMIZED CONTROLLED PRAGMATIC TRIAL TO EVALUATE THE ANTIVIRAL EFFECT OF CHLOROQUINE IN ADULT PATIENTS WITH SARS-COV-2 INFEC... | |||||||||||||
Medical condition: SARS-COV-2 infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NO (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-002991-42 | Sponsor Protocol Number: HCV-13-01 | Start Date*: 2013-12-19 |
Sponsor Name:Foundation for Liver Research | ||
Full Title: Effect of ASV and DCV therapy on the quality of immune status in chronic HCV patients Investigator initiated research proposal nr. AI447-108 | ||
Medical condition: Chronic hepatitis C | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2005-003201-81 | Sponsor Protocol Number: GFVT01026904 (GACHE) | Start Date*: 2006-12-20 |
Sponsor Name:Universitätsklinikum Heidelberg | ||
Full Title: GACHE: German trial of Acyclovir and Corticosteroids in Herpes-simplex-virus-Encephalitis. A multicenter, multinational, randomized, double-blind, placebo-controlled German, Austrian and Dutch trial. | ||
Medical condition: Herpes simplex virus type-1 (HSV-1) is the most frequent cause of fatal sporadic encephalitis in humans. Herpes simplex encephalitis (HSE) was one of the first viral infections to be successfully t... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2020-001934-37 | Sponsor Protocol Number: GLUCOCOVID | Start Date*: 2020-05-07 | |||||||||||
Sponsor Name:IDIVAL Instituto de Investigación Sanitaria Valdecilla | |||||||||||||
Full Title: USE OF CORTICOSTEROIDS IN PATIENTS WITH SARS-COV2 CORONAVIRUS INFECTION (GLUCOCOVID). Pragmatic trial inserted in real practice during a pandemic COVID-19 | |||||||||||||
Medical condition: SARS-CoV-2 infection (COVID-19) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-005981-39 | Sponsor Protocol Number: KMON | Start Date*: 2012-03-20 |
Sponsor Name:Unidad de VIH. Servicio de Enfermedades Infecciosas. Hospital de Bellvitge | ||
Full Title: Pilot simplification study to Lopinavir/ritonavir 800/200 mg monotherapy regimen once daily | ||
Medical condition: HIV-1 positive patients | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: ES (Completed) | ||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
